Literature DB >> 22766897

Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma.

Elika Derek1, Lea Matsuoka, Sophoclis Alexopoulos, Alexander Fedenko, Yuri Genyk, Rick Selby.   

Abstract

PURPOSE: Ocular melanoma is a rare disease with a strong predilection for the liver. Systemic and locoregional treatments for metastatic ocular melanoma have had disappointing results, with an average survival of 5-7 months. Resection and/or radiofrequency ablation (RFA) of liver lesions were attempted to improve the patient outcomes.
METHODS: Eight patients with liver metastasis from ocular melanoma underwent surgery and/or RFA at the University of Southern California, University Hospital from 1 January 2001 to 31 December 2009. Their charts were retrospectively reviewed.
RESULTS: All patients had undergone eye enucleation as the primary treatment. Four patients had all metastatic liver lesions addressed: one patient underwent left lateral segmentectomy and three patients had combinations of left lateral segmentectomies, wedge resections and RFA of two to four lesions. Two patients underwent surgical biopsies for diagnosis, one patient was unresectable and one patient underwent RFA of a dominant lesion. The median survival was 36 months. The median survival of patients who underwent surgery alone or in conjunction with RFA to address all liver lesions was 46 months.
CONCLUSIONS: There are few reports of RFA for metastatic ocular melanoma. RFA of liver lesions in addition to resection can perhaps lead to improved survival and may play a critical role in the future management of this disease.

Entities:  

Mesh:

Year:  2012        PMID: 22766897     DOI: 10.1007/s00595-012-0244-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  35 in total

Review 1.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

2.  Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.

Authors:  R J Salmon; C Levy; C Plancher; T Dorval; L Desjardins; S Leyvraz; P Pouillart; P Schlienger; V Servois; B Asselain
Journal:  Eur J Surg Oncol       Date:  1998-04       Impact factor: 4.424

3.  Long-term survival after radiofrequency ablation of complex unresectable liver tumors.

Authors:  Farin F Amersi; Ana McElrath-Garza; Aziz Ahmad; Theresa Zogakis; David P Allegra; Robert Krasne; Anton J Bilchik
Journal:  Arch Surg       Date:  2006-06

4.  Treatment of liver metastases from uveal melanoma.

Authors:  Michel Rivoire; Laurent Kodjikian; Stefano Baldo; Pierre Kaemmerlen; Sylvie Négrier; Jean-Dominique Grange
Journal:  Ann Surg Oncol       Date:  2005-05-05       Impact factor: 5.344

5.  Radiofrequency ablation of hepatocellular carcinoma: Current status.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  World J Radiol       Date:  2010-11-28

6.  Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.

Authors:  E Berber; E Ari; N Herceg; A Siperstein
Journal:  Surg Endosc       Date:  2005-10-24       Impact factor: 4.584

Review 7.  Locoregional management of hepatic metastasis from primary uveal melanoma.

Authors:  Takami Sato
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

8.  Surgical treatment of metastatic melanoma confined to the liver.

Authors:  D N Papachristou; J J Fortner
Journal:  Int Surg       Date:  1983 Apr-Jun

9.  Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis.

Authors:  Eren Berber; Michael Tsinberg; Gurkan Tellioglu; Conrad H Simpfendorfer; Allan E Siperstein
Journal:  J Gastrointest Surg       Date:  2008-08-08       Impact factor: 3.452

10.  Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.

Authors:  A Y Bedikian; S S Legha; G Mavligit; C H Carrasco; S Khorana; C Plager; N Papadopoulos; R S Benjamin
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

View more
  6 in total

1.  Laparoscopic management of liver metastases from uveal melanoma.

Authors:  Muhammet Akyuz; Pınar Yazici; Cem Dural; Hakan Yigitbas; Alexis Okoh; Emre Bucak; Michael McNamara; Arun Singh; Eren Berber
Journal:  Surg Endosc       Date:  2015-08-27       Impact factor: 4.584

Review 2.  Local treatment of oligometastatic disease: current role.

Authors:  Moritz T Winkelmann; Stephan Clasen; Philippe L Pereira; Rüdiger Hoffmann
Journal:  Br J Radiol       Date:  2019-06-06       Impact factor: 3.039

Review 3.  Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience.

Authors:  Stefan Stättner; Florian Primavesi; Vincent S Yip; Robert P Jones; Dietmar Öfner; Hassan Z Malik; Stephen W Fenwick; Graeme J Poston
Journal:  Surg Today       Date:  2014-03-16       Impact factor: 2.549

4.  Laparoscopic liver resection for metastatic melanoma.

Authors:  Davit L Aghayan; Airazat M Kazaryan; Åsmund Avdem Fretland; Mushegh A Sahakyan; Bård I Røsok; Bjørn Atle Bjørnbeth; Bjørn Edwin
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

Review 5.  Appraisal of Laparoscopic Liver Resection in the Treatment of Liver Metastasis with Special Reference to Outcome in Colorectal Malignancies.

Authors:  Priya Hazrah; Deborshi Sharma; Saurabh Borgharia; Pawan Kumar; Romesh Lal
Journal:  Indian J Surg       Date:  2013-07-25       Impact factor: 0.656

6.  Management of uveal melanoma: a consensus-based provincial clinical practice guideline.

Authors:  E Weis; T G Salopek; J G McKinnon; M P Larocque; C Temple-Oberle; T Cheng; J McWhae; R Sloboda; M Shea-Budgell
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.